Amgen Inc (NASDAQ:AMGN) Q3 2018 Earnings Conference Call - Final Transcript

Oct 30, 2018 • 05:00 pm ET


Amgen Inc (NASDAQ:AMGN) Q3 2018 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript

Q & A
Bob Bradway

by the intellectual property of Enbrel. And we look forward to having an opportunity to validate that intellectual property through this court process.

Okay. I think, let me thank you all for joining us on the call and I hope you can see from our report of the third quarter that we continue to deliver solid financial performance. We're ready for the change in competitive environment that all of us I think and this industry face, focused on developing innovative first-in-class therapies. And we're excited about the 7 that we talked about just having introduced into clinic, doing our parts and working with our colleagues in the industry to improve accessibility and affordability for our products.

And finally, excited about the level of engagement that we continue to enjoy from our staff around the world. So thank you all for your participation in the call. And as usual, our IR team will be standing by if you have any further questions.

David Meline

Thanks everybody.


Ladies and gentlemen, this does conclude the Amgen's third quarter 2018 earnings call. We thanking you greatly for joining us. You may now disconnect.